735MO Updated safety and efficacy from SURPASS, the phase I trial of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in previously treated patients with unresectable or metastatic tumors

• Published in: Annals of oncology Vol. 33; pp. S879 - S880
• Main Authors: Hong, D.S., Asch, A., Calvo, E., Zugazagoitia, J., Charlson, J., Butler, M.O., Moreno Garcia, V., Cervantes, A., Van Tine, B.A., Lawrence, D.P., Johnson, M.L., Lin, Q., Annareddy, T., Brophy, F., Broad, R., Derrac Soria, A., Navenot, J-M., Saro, J., Norry, E., Clarke, J.M.
• Format: Journal Article
• Language: English
• Published: 01.09.2022
• ISSN: 0923-7534
• DOI: 10.1016/j.annonc.2022.07.861